Kidney Involvement of Patients with Waldenström Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders.
暂无分享,去创建一个
D. Dingli | S. Ansell | A. Dispenzieri | S. Rajkumar | S. Nasr | M. Lacy | C. Thompson | F. Buadi | F. Fervenza | D. Jevremovic | P. Kapoor | T. Kourelis | N. Leung | Y. Hwa | W. Gonsalves | R. King | M. Shi | Morie A. Gertz | Larissa Higgins | Samar Said | Robert A. Kyle | Ladan Zand | M. Gertz
[1] F. Petitprez,et al. Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy. , 2017, Blood.
[2] A. Mallett,et al. Monoclonal gammopathy of renal significance triggering atypical haemolytic uraemic syndrome , 2017, Nephrology.
[3] F. Cosio,et al. Outcomes of patients with renal monoclonal immunoglobulin deposition disease , 2016, American journal of hematology.
[4] M. Kersten,et al. Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes , 2016, British journal of haematology.
[5] J. Goujon,et al. Kidney diseases associated with monoclonal immunoglobulin M-secreting B-cell lymphoproliferative disorders: a case series of 35 patients. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[6] E. Kimby,et al. Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop , 2013, British journal of haematology.
[7] I. Ghobrial. Are you sure this is Waldenstrom macroglobulinemia? , 2012, Hematology. American Society of Hematology. Education Program.
[8] A. Dispenzieri,et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. , 2012, Blood.
[9] M. Dimopoulos,et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] A. Dispenzieri,et al. IgM multiple myeloma: Disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia , 2010, American journal of hematology.
[11] T. Habermann,et al. Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. , 2010, Mayo Clinic proceedings.
[12] Benjamin Deroure,et al. Renal lesions associated with IgM-secreting monoclonal proliferations: revisiting the disease spectrum. , 2008, Clinical journal of the American Society of Nephrology : CJASN.
[13] M. Dimopoulos,et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. , 2003, Seminars in oncology.
[14] J. Fraumeni,et al. Waldenström's macroglobulinemia , 1998, Cancer.
[15] P. Verroust,et al. Pathology of the kidney in Waldenström's macroglobulinemia. Study of sixteen cases. , 1970, The New England journal of medicine.
[16] B. Knebelmann,et al. Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome: a retrospective series of 49 patients , 2017, Leukemia.
[17] M. Kersten,et al. Guideline for diagnosis and treatment of Waldenström's macroglobulinaemia. , 2013, The Netherlands journal of medicine.
[18] S. Yamasaki,et al. Renal thrombotic microangiopathies/thrombotic thrombocytopenic purpura in a patient with primary Sjögren’s syndrome complicated with IgM monoclonal gammopathy of undetermined significance , 2010, Rheumatology International.